Changes in LOX and CYP synthetic enzymes do not account for the reported reductions in free proresolving lipids, as postmortem rodent and human studies have shown that these enzymes are in fact elevated in AD (23, 34). The gene discussed is LOX; the disease is Alzheimer disease.